title: Mobilization of peripheral blood stem cells in children using G-CSF after carboplatin containing myelosuppressive chemotherapy.
abstract: OBJECTIVE
  Peripheral blood stem cell (PBSC) apheresis provides an alternative to autologous marrow harvest as a source of hematologic stem cells for transplantation in children with solid tumors.
  
  
  METHODS
  Eight children with metastatic or recurrent solid tumors underwent 27 apheresis procedures. Recovery from myelosuppressive chemotherapy occurred without continuous daily growth factor support prior to mobilization. Granulocyte colony stimulating factor (G-CSF) at 16 microgs/kg/day was used to increase stem cells in the peripheral circulation. CD 34 positive cells, mononuclear cells (MNC), and CFU-GM were measured in the apheresis products. Prior chemotherapy was examined as a clinical factor that affected PBSC yield.
  
  
  RESULTS
  A significant correlation was found between CD 34+/kg and CFU-GM/kg of the products (r = 0.758, P < 0.001). Patients receiving cumulative doses of carboplatin over 1,600 mg/m2 produced adequate MNC (1 x 10(8)/kg) but yielded significantly less CD 34+ cells or CFU-GM than those patients receiving less carboplatin. Prior doses of etoposide and ifosfamide did not effect PBSC yield.
  
  
  CONCLUSIONS
  The mobilization technique was well tolerated, and the products obtained produced trilineage engraftment in the patients that underwent peripheral blood stem cell transplantation. Peripheral blood stem cell apheresis in children can be optimized by selection of appropriate candidates and mobilization with G-CSF after an absence of hematopoietic growth factor support.
authors.affiliation: Department of Pediatrics, Ohio State University College of Medicine, Columbus, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Rauck
authors.forename: F B
authors.initials: FB
authors.lastname: Ruymann
authors.forename: K
authors.initials: K
authors.lastname: Klopfenstein
authors.forename: N
authors.initials: N
authors.lastname: Grossman
authors.forename: R
authors.initials: R
authors.lastname: Rosselet
authors.forename: L
authors.initials: L
authors.lastname: Grovas
authors.forename: S
authors.initials: S
authors.lastname: Ceselski
authors.forename: J
authors.initials: J
authors.lastname: Hayes
authors.forename: A C
authors.initials: AC
authors.lastname: Grovas
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000188:drug therapy*; D016190:Carboplatin / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D016014:Linear Models; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D016190:Carboplatin